Table 1. Clinical characteristics of the study subjects.
| MON-400BUD n=70 | 800BUD n=70 | P | |
|---|---|---|---|
| Gender (M:F) | 31:39 | 32:38 | 1.000 |
| Age (year) | 68.2±5.5 | 67.3±5.1 | 0.315 |
| Body mass index (kg/m2) | 24.6±3.3 | 24.9±2.7 | 0.483 |
| Concurrent rhinitis, n (%) | 19 (27.1) | 22 (31.4) | 0.577 |
| INS users, n (%) | 5 (7.1) | 10 (14.3) | 0.172 |
| Baseline FEV1 (% predicted) | 95.5±26.5 | 95.7±21.3 | 0.966 |
| Baseline MMEF (% predicted) | 60.6±30.7 | 62.9±29.7 | 0.650 |
| Sputum eosinophil % | 7.8±21.8 | 3.6±14.7 | 0.231 |
| Sputum neutrophil % | 55.3±39.4 | 56.3±38.8 | 0.894 |
| ACT score | 18.8±4.6 | 18.6±4.6 | 0.783 |
| Baseline ACT score <20, n (%) | 35 (50) | 28 (40) | 0.234 |
| AQoL | 93.7±19.8 | 90.5±26.0 | 0.391 |
| 6-min walk distance (m) | 412.8±78.1 | 423.5±94.8 | 0.478 |
| Geriatric depression score | 1.6±1.7 | 1.5±1.7 | 0.599 |
| PFS (total) | 86.9±13.2 | 87.9±13.4 | 0.631 |
| PFS (mobility) | 80.2±17.5 | 82.4±17.7 | 0.461 |
| PFS (self-care) | 93.4±12.3 | 93.4±12.2 | 0.984 |
The t test was used for analysis of continuous variables and Fisher's exact test was used for categorical variables.
MON-400BUD, combination therapy consisting of montelukast and low-dose inhaled budesonide; 800BUD, monotherapy consisting of a medium dose of inhaled budesonide; INS, intranasal corticosteroid; FEV1%, percentage of expected volume exhaled at the end of the first second of forced expiration; ACT, asthma control test; AQoL, asthma-specific quality of life questionnaire; PFS, physical functioning scale.